Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Novel TNFα inhibitor, certolizumab pegol
Peter Y. Shane, Sadayoshi Onodera
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel TNFα inhibitor, certolizumab pegol'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
TNF Inhibitors
100%
Certolizumab Pegol
100%
Monoclonal Antibody
20%
Structural Features
20%
Rheumatoid Arthritis
20%
PEGylated
20%
Health-related Quality of Life
20%
Pharmacokinetic Profile
20%
Biological Agents
20%
Humanized
20%
Japan
20%
Rheumatoid Arthritis Treatment
20%
Pharmacodynamics
20%
Fab Fragment
20%
Active Rheumatoid Arthritis
20%
PEGylation
20%
Joint Destruction
20%
Improved Health
20%
Anti-TNF Agents
20%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor Inhibitor
100%
Certolizumab Pegol
100%
Rheumatoid Arthritis
60%
Inflammatory Arthritis
60%
Monoclonal Antibody
20%
Pharmacodynamics
20%
Tumor Necrosis Factor
20%
Biological Product
20%
Physical Disease by Body Function
20%
Immunoglobulin F(ab) Fragment
20%
PEGylation
20%
Joint Destruction
20%
Pharmacokinetics
20%